Highlights and Quick Summary
- Capex/Depreciation for the quarter ending June 29, 2021 was -0.43 (a 54.03% increase compared to previous quarter)
- Year-over-year quarterly Capex/Depreciation decreased by -86.65%
- Annual Capex/Depreciation for 2020 was -2.78 (a -49.62% decrease from previous year)
- Annual Capex/Depreciation for 2019 was -5.52 (a 386.83% increase from previous year)
- Annual Capex/Depreciation for 2018 was -1.13 (a -49.63% decrease from previous year)
- Twelve month Capex/Depreciation ending June 29, 2021 was -0.43 (a -55.53% decrease compared to previous quarter)
- Twelve month trailing Capex/Depreciation decreased by -93.41% year-over-year
Trailing Capex/Depreciation for the last four month:
| 29 Jun '21 | 30 Mar '21 | 30 Dec '20 | 29 Sep '20 |
|---|---|---|---|
| -0.43 | -0.96 | -2.78 | -6.45 |
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Capex/Depreciation of PHASEBIO PHARMA
Most recent Capex/Depreciationof PHAS including historical data for past 10 years.Interactive Chart of Capex/Depreciation of PHASEBIO PHARMA
PHASEBIO PHARMA Capex/Depreciation for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | -0.43 | -0.28 | – | – | – |
| 2020 | -0.16 | -3.24 | -9.14 | -12.19 | -2.78 |
| 2019 | -2.72 | -7.9 | -8.02 | -2.71 | -5.52 |
| 2018 | -3.83 | -0.11 | -0.81 | -0.22 | -1.13 |
| 2017 | – | – | -0.43 | -3.0 | -2.25 |
| 2016 | – | – | – | – | 0.0 |
Business Profile of PHASEBIO PHARMA
Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.